A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

@article{Cazenave2010ARC,
  title={A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology},
  author={J‐P. Cazenave and Gilles Foll{\'e}a and Laurent Bardiaux and Jean Michel Boiron and Bruno Lafeuillade and M. Debost and Bruno Lioure and J. L. Harousseau and Resa Tabrizi and J. Y. Cahn and Marie-C{\'e}cile Michallet and Daniel R. Ambruso and R. Schots and J-D Tissot and Luc Sens{\'e}b{\'e} and Toshinori Kondo and J. Mccullough and Paolo Rebulla and Gin{\'e}s Escolar and Paul D Mintz and Nancy M. Heddle and Raymond P. Goodrich and Jacques Bruhwyler and C. Le and Richard J. Cook and Bruce C. Stouch},
  journal={Transfusion},
  year={2010},
  volume={50}
}
BACKGROUND: Pathogen reduction of platelets (PRT‐PLTs) using riboflavin and ultraviolet light treatment has undergone Phase 1 and 2 studies examining efficacy and safety. This randomized controlled clinical trial (RCT) assessed the efficacy and safety of PRT‐PLTs using the 1‐hour corrected count increment (CCI1hour) as the primary outcome. 
Meta‐analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen‐reduced platelets
TLDR
Meta‐analysis was used to calculate the effect of pathogen reduction of PLTs on hemostatic efficacy and capacity based on all available data and to investigate possible reasons for the variation in reported findings. Expand
Efficacy and safety of pathogen‐reduced platelet concentrates in children with cancer: a retrospective cohort study
TLDR
The results of a retrospective evaluation of prophylactic transfusions of PR PLT units treated with riboflavin and ultraviolet light in pediatric patients with malignant disorders are reported. Expand
Clinical trials evaluating pathogen‐reduced platelet products: methodologic issues and recommendations
Several randomized trials of platelet (PLT) products have been conducted with different study designs, endpoints, and analyses. The purpose of this article is to discuss methodologic issues in theExpand
Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions
TLDR
This study objective was to evaluate the count increments of PRT‐treated P AS‐C and PAS‐E buffy coat (BC) PLTs in routine use observational settings. Expand
Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta‐analysis of randomized controlled trials
TLDR
A meta‐analysis is performed to summarize the results of different randomized controlled trials (RCT) on the therapeutic efficacy of platelets inactivated using amotosalen and ultraviolet A light. Expand
Clinical effectiveness of platelets in additive solution treated with two commercial pathogen‐reduction technologies
Two noninferiority, randomized, controlled trials were conducted in parallel comparing the safety and efficacy of platelets treated with Intercept or Mirasol pathogen‐reduction technologies versusExpand
PLATELET TRANSFUSION EFFICACY FOLLOWING PATHOGEN REDUCTION TREATMENT : AN ITALIAN RANDOMIZED CONTROLLED TRIAL
The primary endpoint for each trial was the percentage of patients who experienced World Health Organization Grade 2 or greater bleeding. A noninferiority margin of 11% was chosen based on anExpand
A pilot study to assess the hemostatic function of pathogen‐reduced platelets in patients with thrombocytopenia
TLDR
This clinical pilot study assessed the effect of pathogen reduction technology with riboflavin plus ultraviolet light using thrombelastography (TEG) on PLT function in patients with thrombocytopenia. Expand
Meta‐analysis of the studies of bleeding complications of platelets pathogen‐reduced with the Intercept system
TLDR
The eligibility criteria of a previously reported meta‐analysis of randomized controlled trials of pathogen reduction of platelets in patients with hypoproliferative thrombocytopenia were modified to examine the impact on the findings of inclusion of a RCT and differences in the methods used to assess bleeding complications. Expand
The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover
TLDR
The aim of this study was to examine the effect of PRT on the platelet storage lesion, in the presence of PAS with low plasma carryover. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets
TLDR
This study evaluates the effectiveness of plasma removal and two methods of prestorage WBC reduction for preventing acute reactions to platelets. Expand
Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction
TLDR
The efficacy of apheresis PLTs treated with riboflavin plus ultraviolet (UV) light was investigated in a single‐blind, crossover study in comparison to untreated PLTs. Expand
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.
TLDR
The incidence of grade 2 bleeding was equivalent for PCT and conventional platelets, although posttransfusion platelet count increments and days to next transfusion were decreased for P CT compared with conventional platelet transfusions. Expand
The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends.
TLDR
Current progress and future trends are reviewed in the Mirasol PRT process, a novel pathogen reduction process for platelets and plasma products, based on riboflavin photochemistry. Expand
Effects of Mirasol PRT treatment on storage lesion development in plasma‐stored apheresis‐derived platelets compared to untreated and irradiated units
BACKGROUND: The aim of this study was to examine the effects of a new riboflavin‐based pathogen reduction technology (PRT), the Mirasol PRT process (Navigant Biotechnologies) on platelet (PLT)Expand
Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen‐reduction technology‐treated apheresis platelet products
TLDR
The aim of this study was to evaluate the effects of the treatment process on in vitro cell quality and on riboflavin conversion in PC. Expand
Assessing the effectiveness of whole blood–derived platelets stored as a pool: a randomized block noninferiority trial
TLDR
The in vivo effect of the prestorage pooling of PLTs stored for up to 5 days is evaluated, by assessing the corrected count increment (CCI) 18 to 24 hours after transfusion of the product. Expand
A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia.
TLDR
A higher rate of grade 4 bleeding in patients receiving low-dose prophylactic platelet transfusions resulted in this RCT being stopped, and whether this finding was due to chance or represents a real difference requires further investigation. Expand
A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns
BACKGROUND: Concerns over the risk of bacterial contamination of platelet products have led to implementation of bacteria culture and other screening methods. New approaches for dealing with thisExpand
BLOOD COMPONENTS: Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light–treated platelet concentrates
TLDR
Serum of patients who received PRT‐treated platelet (PLT) concentrates over a time period of 28 days is evaluated for the appearance of antibodies to neoantigens on PLTs to help assess the risk of transfusion‐transmitted infectious diseases. Expand
...
1
2
3
4
5
...